Navigation Links
Call Center Workers At An Increased Risk Of Breast Cancer

Noel Colina, the executive director at the Institute for Occupation Health and Safety Development says that women who work in night shifts are more prone //to develop breast cancer. Citing a study by US-based Fred Hutchinson Cancer Research Center, Colina said that a number of women were taking up work in the graveyard shift - usually from 6 p.m. to 6 a.m.

This type of work usually done at call centers placed them at a high risk for developing breast cancer. "Nighttime sleep deprivation or exposure to light at night somehow interrupts melatonin production, which in turn stimulates the ovaries to kick out extra estrogen, a known hormonal promoter of breast cancer," he said. Colina added that the study had showed that the risk of developing the cancer increased by as much as 60 percent.

Nighttime work may also play havoc with the menstrual cycle. "Painful menstruation (dysmenorrhea), absence of menstruation (amenorrhea), and heavy menstruation (menorrhagia) are conditions associated with women taking the graveyard shift," Colina said. "Although the study isn't conclusive, it provides us [with] pointers on how to address and protect the occupational health and safety of working women at call centers."

Call centers must take a note of the study and provide free and regular breast cancer screening for their employees, he added.


'"/>




Page: 1

Related medicine news :

1. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
2. Osaka Medical Center study showed 70% of smokers couldn’t qui
3. Kalam To Lay Foundation Of Vellore Research Center
4. Free Treatment Center Established In Chennai
5. Analyzing Client-Centered Therapy.
6. Human Milk Center Caters To Premature Babies
7. Walk-In Health Centers Launched By The NHS For Commuters
8. Free HIV Tests Brings Crowd to the Testing Centers
9. Kerala To Become Testing Center For US Bound Nurses
10. Himachal Pradesh Fails To Become Health Tourism Center
11. Vanderbilt-Ingram Cancer Center To Study Ways To Prevent Chemo Brain
Post Your Comments:
(Date:12/5/2008)... RICHMOND HILL, ON, Dec. 5 /PRNewswire/ - Norgine,...pany, has today announced that it has granted Medi...P(R) in Canada. , MOVIPREP is a novel patent-pr...ansing prior to colonoscopy and other situations w...keted by Norgine in Europe and in the USA by its p...
(Date:12/5/2008)... BELLUS Health Receives NASDAQ Deficiency Notice R...--------------------------------------------------...ll/ - BELLUS Health Inc. (NASDAQ: BLUS ; TSX: BL...nt fluctuations in world capital markets, the Comp...SDAQ Capital Market, while continuing to maintain ...
(Date:12/5/2008)..., Dr. Alan Greene from th...ar milestone of eating only organic food. It,s the...tified 100% organic. , Da... animals can be certified organic by the Departmen...n and author Dr. Alan Greene, why not people?, , ,...
(Date:12/4/2008)..., Early detection of lung disease in cystic fibro...fants, may be the key to controlling the progressi...w research shows that contrary to previous scienti...s can begin as early as infancy even though lung f...e might be able to stop some of the lung function ...
Breaking Medicine News(10 mins):Health News:Medical Futures partners with Norgine for MOVIPREP(R) in Canada 2Health News:BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market 2Health News:BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market 3Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 2Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 3Health News:Intervention in infants with cystic fibrosis key to slowing progression 2Health News:Intervention in infants with cystic fibrosis key to slowing progression 3
...e WHO has issue a checklist for doctors and nurse ...s. Basic mistakes like not washing hands by the h...arters. The WHOs 9 solution is meant to improve p...essen the number of health care related accidents ...
...e Delhi High Court Wednesday held that the misuse ...taff would be viewed seriously, stressing that th...ision bench of Justice T.S. Thakur and Justice S.N... of the hospitals of both state and central govern...
...California-based Keralite doctor has bagged this y...the National Ethnic Coalition of Organisations (NE... award May 12, said he was "really delighted". "Th...o be a boost for all my future endeavours," Eapen ...
...ldiers returning from Iraq who have migraine heada...mptoms of post-traumatic stress, depression or anx...ording to research. The study involved 3,621 Unite...en a health screening questionnaire within 90 days...
Other Medicine News:Health News:UN Agencys Checklist on Health Care Error 2Health News:Migraines may Be a Symptom of Other Problems for Iraq Soldiers 2
(Date:12/3/2008)..., Dec. 3 Isogen, a contract develo...filling, announced it has retained a,strategic fi...et the global,biopharma demand for Isogen,s servi...ccessful first round series of capital,investment...y in Q1 2009 to,deliver on the previously unmet p...
(Date:12/3/2008)...Calif., Dec. 3 Bionovo, ...DA has reviewed the company,s,manufacturing and c...d,guidance on how Bionovo can move forward with t...for menopausal hot flashes. , "We have conc...moving to,address the Agency,s recommendations fo...
(Date:12/2/2008).... 3 Researchers using f...cuitry in the area of the brain,responsible for s...fering from,stress-related psychiatric disorders....the annual meeting of the Radiological Society of ... major depression and other stress-related disorde...
(Date:12/2/2008)...ass., Dec. 2 Biopure Cor...he U.S. Naval Medical Research Center,(NMRC) has ...) a revised,investigational new drug (IND) applic...s oxygen therapeutic Hemopure(R) [hemoglobin gluta...eld treatment of trauma patients. The study is,en...
Breaking Medicine Technology:Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 2Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 2Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 4Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3BrainCells Inc Completes 2430 Million Initial Closing of Series B Financing 3816 1BrainCells Inc Completes 2430 Million Initial Closing of Series B Financing 3816 2Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 1Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 2Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 3Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 4Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 5Palatin Technologies Inc Reports Positive Results of a Phase I Clinical Study With PL 3994 for the Treatment of Congestive Heart Failure 3811 1Palatin Technologies Inc Reports Positive Results of a Phase I Clinical Study With PL 3994 for the Treatment of Congestive Heart Failure 3811 2Palatin Technologies Inc Reports Positive Results of a Phase I Clinical Study With PL 3994 for the Treatment of Congestive Heart Failure 3811 3Palatin Technologies Inc Reports Positive Results of a Phase I Clinical Study With PL 3994 for the Treatment of Congestive Heart Failure 3811 4Fralex reaches 100th patient milestone in fibromyalgia study 3810 1Fralex reaches 100th patient milestone in fibromyalgia study 3810 2Fralex reaches 100th patient milestone in fibromyalgia study 3810 3
...pril 2007. Giaconda Ltd (ASX: GIA) today,announced...s,approved the Company,s Investigational New Drug ...MyocondaR to treat patients with,Crohn,s Disease i...sis (MAP). , ,The Company understands that its lea...ubmitted to the FDA for this indication. There,are...
... 160th Annual Meeting of the American,Psychiatric ...-FirstCall/ -- In adults with,major depressive dis...py (ADT) resulted in significant improvement in th...ion Rating Scale (MADRS),Total Score. In this six-...ed here at the 160th Annual Meeting of the America...
Other Medicine Technology:FDA approves MyocondaR IND for MAP in Crohn's Disease 2FDA approves MyocondaR IND for MAP in Crohn's Disease 3FDA approves MyocondaR IND for MAP in Crohn's Disease 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8
The unique MR-frame and its indicators are made of a highly tensile and fibre reenforced Epoxyd material.
Table-mounted, retraction for radiolucent anterior spine procedures. Fully-adjustable for any approach and any patient. Combine with our radiolucent blade kit for optimal visibility.
VG2 PLIF (Parallel) Posterior lumbar interbody fusion. Frozen preservation. Consists of two outer cortical planks, center cancellous plank, all from the same donor, held together by two press-fit cor
VG1 ALIF (Anterior) Anterior lumbar interbody fusion. Frozen freeze-dried preservation.
Medicine Products: